| Drug ID: | Drug46 |
|---|---|
| Drug Name: | Neomycin |
| CID: | 8378 |
| DrugBank ID: | DB00994 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT02765256, , NCT00355602 |
| Molecular Formula: | C23H46N6O13 |
| Molecular Weight: | 614.6 g/mol |
| Isomeric SMILES: | C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N |
| Synonyms: | Framycetin; neomycin; NEOMYCIN B; 119-04-0; Fradiomycin; Mycifradin; Soframycin; NEOMYCIN SULFATE; Enterfram; Framygen |
| Phase 0: | 5 |
| Phase 1: | 4 |
| Phase 2: | 8 |
| Phase 3: | 5 |
| Phase 4: | 8 |
| Description: | A component of neomycin that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). Neomycin is a bactericidal aminoglycoside antibiotic that binds to the 30S ribosome of susceptible organisms. Binding interferes with mRNA binding and acceptor tRNA sites and results in the production of non-functional or toxic peptides. |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt423 | 8378 | Framycetin | 1161 | ERCC8 | Homo sapiens (human) | Inhibitor | |
| dt424 | 8378 | Framycetin | 2434 | FRA10D | Homo sapiens (human) | Inhibitor | |
| dt425 | 8378 | Framycetin | 3791 | KDR | Homo sapiens (human) | 17441906 | None |
| dt426 | 8378 | Framycetin | 1815 | DRD4 | Homo sapiens (human) | Inhibitor | |
| dt427 | 8378 | Framycetin | 45025515 | lef | Bacillus anthracis | 16386899 | None |
| dt428 | 8378 | Framycetin | 45025515 | lef | Bacillus anthracis | 16870442 | None |
| dt429 | 8378 | Framycetin | 24247 | Casr | Rattus norvegicus (Norway rat) | 7816802 | Full agonist |
| dt430 | 8378 | Framycetin | None | -- | None | 11983334 | None |
| dt431 | 8378 | Framycetin | 846 | CASR | Homo sapiens (human) | 17537980 | None |
| dt432 | 8378 | Framycetin | 595 | CCND1 | Homo sapiens (human) | Agonist |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT02765256 | Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease | PHASE2 | COMPLETED | University of Pennsylvania | Crohn's Disease | DRUG: Fluconazole|DRUG: Vancomycin|DRUG: Neomycin… | Details |
| NCT03042091 | Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery | EARLY_PHASE1 | UNKNOWN | Thomas Jefferson University | Colorectal Neoplasms; Diverticulitis; Inflammator… | DRUG: Polyethylene Glycol; DRUG: Neomycin; DRUG: … | Details |
| NCT00355602 | Antibiotics for the Treatment of Ulcerative Colitis | None | COMPLETED | University of Dundee | Colitis, Ulcerative | DRUG: Cefuroxime|DRUG: Ciprofloxacin|DRUG: Clarit… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S03 | Anti-TNF agents | Tumor necrosis factor | infliximab; adalimumab; golimumab; certolizumab pegol | TNF is produced by various immune and non-immune cells in t… | Details |
| S04 | T-cell homing and retention | T-cell trafficking | vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab | Inhibition of the interaction between α4β7 integrins on T c… | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
| S11 | Improveming Intestinal Microecology | the intestinal microbiota | antibiotics; probiotics; prebiotics; postbiotics; synbiotics; fecal microbiota transplantation (FMT) | The imbalance between beneficial bacteria and harmful patho… | Details |
No related literature
You can run management commands to establish drug-literature associations